- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06314334
Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma
A Multicenter, Randomized, Controlled Phase II Screening Study of Combined Sequential Chemotherapy and Radiation Therapies for Early-stage Natural Killer/T-cell Lymphoma (IE/IIE)
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Rong Tao, MD
- Phone Number: 8621-64175590
- Email: rtao@shca.org.cn
Study Contact Backup
- Name: Chuanxu Liu, MD
- Phone Number: 021-64175590
- Email: liuchuanxu@shca.org.cn
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Recruiting
- Fudan University Shanghai Cancer Center
-
Principal Investigator:
- Rong Tao, MD
-
Contact:
- Rong Tao, MD
- Phone Number: 8621-64175590
- Email: rtao@shca.org.cn
-
Contact:
- Chuanxu Liu, MD
- Phone Number: 8621-64175590
- Email: liuchuanxu@shca.org.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients who meet the diagnostic criteria for NKTCL (WHO-2016) based on pathological examination.
- Primary lesions located in the upper respiratory and digestive tract such as the nasal cavity, sinuses, nasopharynx, oropharynx, or oral cavity, with clinical staging of IE/IIE based on PET/CT and bone marrow examination according to the Lugano 2014 criteria.
- Evaluated for lymphoma response according to the Lugano 2014 criteria, with at least one measurable lesion or lesion assessable by PET/CT.
- No prior treatment with chemotherapy, radiotherapy, immunotherapy, or biological therapy for lymphoma.
- Age between 18 and 75 years, both genders.
- Eastern Cooperative Oncology Group performance status (ECOG) score of 0-2.
- Must have adequate organ and bone marrow function, defined as follows:
Hematology: Absolute neutrophil count (ANC) ≥1.0×10^9/L, platelet count (PLT) ≥75×10^9/L, hemoglobin (Hb) ≥90g/L; no administration of granulocyte colony-stimulating factor, platelet transfusion, or red blood cell transfusion in the previous 14 days.
Liver function: Total bilirubin (TBIL) ≤1.5 times the upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2×ULN.
Renal function: Serum creatinine (Cr) ≤1.5×ULN. Coagulation function: Plasma fibrinogen ≥1.5g/L. Cardiac function: Left ventricular ejection fraction (LVEF) ≥50%, no acute myocardial infarction, arrhythmia, or atrioventricular conduction block of grade I or above on electrocardiogram.
- Willing to comply with the study protocol, follow-up plan, and laboratory and ancillary investigations.
Exclusion Criteria:
- Patients co-infected with HCV, HIV, or HBV with plasma HBV-DNA >10^3/ml.
- Patients with a history of pancreatitis.
- Patients with acute or systemic infections requiring intravenous antibiotic therapy.
- Patients with severe complications such as hemophagocytic syndrome, DIC, etc.
- Significant organ dysfunction: such as respiratory failure, chronic congestive heart failure with NYHA class ≥2, decompensated liver or renal dysfunction, uncontrolled hypertension and diabetes despite aggressive treatment, and cardiovascular thrombotic or hemorrhagic events in the past 6 months.
- Patients with a history of autoimmune diseases who are not suitable for treatment with immune checkpoint inhibitors.
- Pregnant and lactating women.
- Patients with psychiatric disorders.
- Known allergies to drugs in the chemotherapy regimen.
- Patients with concomitant other tumors requiring surgery or chemotherapy within the past 6 months.
- Currently using other experimental drugs.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A (synchronous treatment group)
Patients received 4 cycles of Sintilimab combined with pegaspargase therapy, with each cycle lasting 3 weeks, for a total of 4 cycles.
Concurrently, they received radiotherapy treatment (IMRT, 50-56Gy, starting within 21 days after the first Sintilimab treatment).
|
Intensity modulated radiotherapy (50-56Gy)
|
Experimental: Group B (sequential treatment group)
Patients received 4 cycles of the PGEMOX regimen chemotherapy.
Each cycle lasted 3 weeks, with sequential radiotherapy (IMRT, 50-56Gy) administered within 4 weeks after the last chemotherapy cycle.
|
Intensity modulated radiotherapy (50-56Gy)
|
Experimental: Group C (sandwiched radiotherapy group)
Patients received 2 cycles of the GELAD regimen chemotherapy initially, with each cycle lasting 3 weeks.
After the second cycle of chemotherapy, radiotherapy (IMRT, 50-56Gy) was administered within 4 weeks.
Following the completion of radiotherapy, they received an additional 2 cycles of the GELAD regimen chemotherapy.
|
Intensity modulated radiotherapy (50-56Gy)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PFS24
Time Frame: From date of randomization until the date of first documented progression, assessed up to 24 months by the Lugano 2014 response criteria.
|
Rate of patients with 24-month progression-free survival
|
From date of randomization until the date of first documented progression, assessed up to 24 months by the Lugano 2014 response criteria.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR
Time Frame: response rate at 24th week
|
Overall response rate
|
response rate at 24th week
|
OS
Time Frame: From the time of patient randomization to the end of study, assessed up to 60 months
|
Overall survival
|
From the time of patient randomization to the end of study, assessed up to 60 months
|
EFS
Time Frame: From the time of patient randomization to the end of study, assessed up to 60 months
|
Event-free survival
|
From the time of patient randomization to the end of study, assessed up to 60 months
|
TRAE
Time Frame: From the time of patient randomization to the end of study, assessed up to 60 months
|
Treatment-related adverse event related to the study drug or intervention
|
From the time of patient randomization to the end of study, assessed up to 60 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Rong Tao, MD, Fudan Cancer Hospital
Publications and helpful links
General Publications
- Zhu Y, Tian S, Xu L, Ma Y, Zhang W, Wang L, Jin L, Liu C, Zhu C, Li Z, Hao S, Zhong H, Ding H, Tao R. GELAD chemotherapy with sandwiched radiotherapy for patients with newly diagnosed stage IE/IIE natural killer/T-cell lymphoma: a prospective multicentre study. Br J Haematol. 2022 Feb;196(4):939-946. doi: 10.1111/bjh.17960. Epub 2021 Nov 21.
- Zhang Y, Ma S, Cai J, Yang Y, Jing H, Shuang Y, Peng Z, Li B, Liu P, Xia Z, Xia Y, Gao Y, Chen D, Lin J, Li Q, Xu S, Xu Q, Zhang H, Huang H, Cai Q. Sequential P-GEMOX and radiotherapy for early-stage extranodal natural killer/T-cell lymphoma: A multicenter study. Am J Hematol. 2021 Nov 1;96(11):1481-1490. doi: 10.1002/ajh.26335. Epub 2021 Sep 13.
- Wang H, Wang L, Li C, Wuxiao Z, Chen G, Luo W, Lu Y. Pegaspargase Combined with Concurrent Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Two-Center Phase II Study. Oncologist. 2020 Nov;25(11):e1725-e1731. doi: 10.1634/theoncologist.2020-0144. Epub 2020 Jul 29.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SHCA-NKT-202301
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
-
Xinhua Hospital, Shanghai Jiao Tong University...CompletedNatural Killer/T-Cell Lymphoma, Nasal and Nasal-TypeChina
-
Rong TaoRecruitingNatural Killer/T-Cell Lymphoma, Nasal and Nasal-TypeChina
-
Xinhua Hospital, Shanghai Jiao Tong University...CompletedNatural Killer/T-Cell Lymphoma, Nasal and Nasal-TypeChina
-
Mingzhi ZhangUnknownNatural Killer/T-Cell Lymphoma, Nasal and Nasal-TypeChina
-
Rong TaoRecruitingNatural Killer/T-Cell Lymphoma, Nasal and Nasal-TypeChina
-
Cancer Institute and Hospital, Chinese Academy...UnknownNatural Killer/T-Cell Lymphoma, Nasal and Nasal-TypeChina
-
The University of Hong KongUnknownNatural Killer/T-Cell Lymphoma, Nasal and Nasal-Type | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin T-cell LymphomaHong Kong
-
Sun Yat-sen UniversityCompletedRadiotherapy | Sintilimab | Anlotinib | Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type | Early Stage | Peg-aspargase | Phase Two | OpenChina
-
Won Seog KimSanofiRecruitingNatural Killer/T-cell Lymphoma | Relapsed Natural Killer/T-cell Lymphoma | Refractory Natural Killer/T-cell LymphomaKorea, Republic of
-
Beijing Tongren HospitalRecruitingT-lymphoblastic Lymphoma | Natural Killer/T-Cell Lymphoma, Nasal and Nasal-TypeChina
Clinical Trials on Sintilimab+Pegaspargase
-
Rong TaoRecruitingNatural Killer/T-Cell Lymphoma, Nasal and Nasal-TypeChina
-
Sun Yat-sen UniversityRecruitingNK/T Cell Lymphoma NosChina
-
Beijing Tiantan HospitalRecruiting
-
RemeGen Co., Ltd.Recruiting
-
Innovent Biologics (Suzhou) Co. Ltd.CompletedAdvanced or Metastatic NSCLCChina
-
Innovent Biologics (Suzhou) Co. Ltd.Innovent Biologics (USA), Inc.WithdrawnMetastatic Cutaneous Melanoma | Unresectable Cutaneous MelanomaUnited States, Germany, France, Australia, Spain, Switzerland, United Kingdom
-
Zhejiang Cancer HospitalRecruitingEsophageal Squamous Cell CarcinomaChina
-
Peking Union Medical College HospitalRecruiting
-
The First Hospital of Jilin UniversityActive, not recruitingLocally Advanced Rectal Cancer | PD-1 | Total Neoadjuvant Treatment | TislelizumabChina
-
Innovent Biologics (Suzhou) Co. Ltd.Completed